ATE339956T1 - Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin - Google Patents

Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin

Info

Publication number
ATE339956T1
ATE339956T1 AT95943722T AT95943722T ATE339956T1 AT E339956 T1 ATE339956 T1 AT E339956T1 AT 95943722 T AT95943722 T AT 95943722T AT 95943722 T AT95943722 T AT 95943722T AT E339956 T1 ATE339956 T1 AT E339956T1
Authority
AT
Austria
Prior art keywords
allergic rhinitis
descarboethoxyloratadine
agents
treatment
diseases containing
Prior art date
Application number
AT95943722T
Other languages
English (en)
Inventor
A K Gunnar Aberg
John R Mccullough
Emil R Smith
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23443929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE339956(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of ATE339956T1 publication Critical patent/ATE339956T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95943722T 1994-12-30 1995-12-11 Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin ATE339956T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/366,651 US5595997A (en) 1994-12-30 1994-12-30 Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Publications (1)

Publication Number Publication Date
ATE339956T1 true ATE339956T1 (de) 2006-10-15

Family

ID=23443929

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95943722T ATE339956T1 (de) 1994-12-30 1995-12-11 Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin

Country Status (22)

Country Link
US (2) US5595997A (de)
EP (3) EP1078633A3 (de)
JP (1) JP4237822B2 (de)
KR (1) KR100442675B1 (de)
CN (2) CN1935141B (de)
AT (1) ATE339956T1 (de)
AU (1) AU707541B2 (de)
BR (1) BR9510129A (de)
CA (1) CA2208836C (de)
CZ (1) CZ293068B6 (de)
DE (2) DE69535234T2 (de)
DK (1) DK0799037T3 (de)
ES (1) ES2144980T3 (de)
FI (1) FI972781A (de)
HK (1) HK1008185A1 (de)
HU (1) HU229871B1 (de)
MX (1) MX9704793A (de)
NO (3) NO317555B1 (de)
NZ (1) NZ300398A (de)
PT (1) PT799037E (de)
SK (3) SK284834B6 (de)
WO (1) WO1996020708A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163121A1 (en) * 1993-06-14 1994-12-22 Paul Marie Victor Gilis Extended release, film-coated tablet of astemizole and pseudoephedrine
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US7211582B1 (en) * 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US7214683B1 (en) * 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
NZ331160A (en) * 1996-02-08 2000-07-28 Merck & Co Inc use of loratadine and a leukotriene antagonist to treat asthma
CZ150999A3 (cs) * 1996-10-31 1999-10-13 Schering Corporation Farmaceutický prostředek pro léčbu astmatu obsahující loratadin a dekongestant
US6324267B1 (en) 1997-01-17 2001-11-27 Scientific-Atlanta, Inc. Two-tiered authorization and authentication for a cable data delivery system
TW522014B (en) * 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
AU776837B2 (en) * 1997-02-07 2004-09-23 Sunovion Pharmaceuticals Inc. Lactose-free non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6140337A (en) 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
DE69835103T2 (de) * 1997-12-23 2006-12-21 Schering Corp. Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
EP0968715B1 (de) * 1998-06-30 2004-09-01 Pfizer Products Inc. Loratadin zur Verwendung als Antiarrhythmikum
WO2000002560A1 (en) 1998-07-10 2000-01-20 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE ORAL COMPOSITIONS
WO2000015226A1 (en) * 1998-09-10 2000-03-23 Schering Corporation Antihistamines for treating non-infective sinusitis or otitis media
WO2000057880A1 (en) * 1999-03-29 2000-10-05 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
WO2001021161A2 (en) * 1999-09-21 2001-03-29 Schering Corporation Use of desloratadine for treating allergic and inflammatory conditions
PE20010752A1 (es) * 1999-09-22 2001-07-17 Schering Corp Uso de desloratadina para el tratamiento de estados alergicos e inflamatorios
AR025964A1 (es) * 1999-10-08 2002-12-26 Schering Corp Tratamiento nasal topico
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
WO2001045688A2 (en) * 1999-12-21 2001-06-28 Schering Corporation Use od desloratadine for treating allergic and inflammatory conditions in pediatric patients
EP1251851A1 (de) * 2000-02-03 2002-10-30 Schering Corporation Die behandlung von allergischen und entzündlichen erkrankungen
US7405223B2 (en) * 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
AU2001255268A1 (en) * 2000-04-07 2001-10-23 Schering Corporation Inhibition of cytokine generation
AU2002256967A1 (en) * 2000-10-30 2002-09-12 Schering Corporation Treating or reducing the risk of cardiovascular disease
WO2002036124A2 (en) * 2000-10-30 2002-05-10 Schering Corporation Treatment and method using loratadine and montelukast
WO2002036077A2 (en) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US6599914B2 (en) * 2001-04-24 2003-07-29 Schering Corporation Inhibition of cytokine generation
US20030236275A1 (en) * 2002-06-20 2003-12-25 Schering Corporation Treatment methods of nasal congestion and nasal obstruction
US6720002B2 (en) * 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
CN1571664A (zh) * 2001-10-17 2005-01-26 久光制药株式会社 经皮吸收型制剂
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
MXPA04005417A (es) * 2001-12-05 2004-10-11 Alcon Inc Uso de antagonista de h1 y un esteroide seguro para el tratamiento de la rinitis.
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
US20030004179A1 (en) * 2002-05-21 2003-01-02 Affrime Melton B Treating allergic and inflammatory conditions
CA2494288A1 (en) * 2002-08-05 2004-02-12 Sandoz Ag Novel salt and polymorphs of desloratadine hemifumarate
DE60217934T2 (de) * 2002-09-24 2007-05-24 Morepen Laboratories Ltd. Verfahren zur herstellung von desloratadin
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
EP1817307A2 (de) * 2004-07-07 2007-08-15 Egis Gyogyszergyar Rt. Neues, mit kohlendioxid gebildetes pseudopolymorph von desloratadin
US20070281960A1 (en) * 2004-07-16 2007-12-06 Amar Lulla Anti-Histaminic Composition
US20060154948A1 (en) * 2005-01-12 2006-07-13 Schering Corporation Treating allergic and inflammatory conditions
CA2541045A1 (en) * 2006-03-24 2007-09-24 Pharmascience Inc. A descarbonylethoxyloratadine containing pharmaceutical composition
BRPI0712532A2 (pt) 2006-06-01 2013-04-02 Schering Plough Healthcare Prod Inc formulaÇÕes e composiÇÕes farmacÊuticas de fenilefrina para absorÇço colânica
EP2120945A1 (de) * 2007-02-28 2009-11-25 Collegium Pharmaceutical, Inc. Antihistamin-kombination
WO2009020620A1 (en) * 2007-08-06 2009-02-12 Bridge Pharma, Inc. Synergisms between repartitioning and immunomodulating compounds
CA2704728A1 (en) * 2007-09-18 2009-03-26 Stephen Wills Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors
US8321151B2 (en) 2008-12-30 2012-11-27 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
US8073633B2 (en) * 2008-12-30 2011-12-06 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
US8315815B2 (en) 2008-12-30 2012-11-20 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
TW201111392A (en) 2009-06-16 2011-04-01 Schering Corp Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
ATE525064T1 (de) 2009-07-01 2011-10-15 Tiefenbacher Alfred E Gmbh & Co Kg Pharmazeutische zusammensetzung mit desloratadin
CA2690490C (en) 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
US8778971B2 (en) 2012-10-23 2014-07-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in companion animals
US8557846B1 (en) 2012-10-23 2013-10-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in dogs
US20150272941A1 (en) 2012-10-30 2015-10-01 Bridge Pharma, Inc. Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
US20140120121A1 (en) 2012-10-30 2014-05-01 Bridge Pharma, Inc. Medicinal treatment of atopic inflammatory diseases
US9138431B2 (en) 2013-08-06 2015-09-22 Bridge Pharma, Inc. Methods of treatment of histamine H-4 receptor-related pruritus
US9345697B2 (en) 2013-08-06 2016-05-24 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus
US9439895B2 (en) 2013-08-06 2016-09-13 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients
IT201900012645A1 (it) * 2019-07-23 2021-01-23 Eros Zanotti Una composizione farmaceutica per l'uso nel trattamento delle chinetosi

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
JPS61501205A (ja) * 1984-02-15 1986-06-19 シェリング・コ−ポレ−ション ８↓−クロル↓−６，１１↓−ジヒドロ↓−１１↓−（４↓−ピペリジリデン）↓−５Ｈ↓−ベンゾ〔５，６〕シクロヘプタ〔１，２−ｂ〕ピリジンおよびその塩、これらの化合物の製造方法、ならびにこれらの化合物を含有する医薬組成物
US4804666A (en) * 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
NZ238629A (en) * 1990-06-22 1993-09-27 Schering Corp Bis-benzo- or benzopyrido-cyclohepta (where z is c, o, s or n) piperidine, piperidylidene or piperazine compounds, medicaments and methods of preparation
AU665341B2 (en) * 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance

Also Published As

Publication number Publication date
NO20020211L (no) 1997-08-19
PT799037E (pt) 2006-12-29
FI972781A0 (fi) 1997-06-27
JPH10512240A (ja) 1998-11-24
DE69535234D1 (de) 2006-11-02
EP1078633A2 (de) 2001-02-28
NO20020211D0 (no) 2002-01-15
CZ202697A3 (cs) 1998-03-18
JP4237822B2 (ja) 2009-03-11
CN1176598A (zh) 1998-03-18
SK284834B6 (sk) 2005-12-01
US5731319A (en) 1998-03-24
CZ293068B6 (cs) 2004-02-18
SK286079B6 (sk) 2008-03-05
SK287257B6 (sk) 2010-05-07
US5595997A (en) 1997-01-21
NO20110077L (no) 1997-08-19
DE69535234T2 (de) 2007-09-13
BR9510129A (pt) 1997-12-30
ES2144980T1 (es) 2000-07-01
FI972781A (fi) 1997-08-27
HUT77315A (hu) 1998-03-30
HU229871B1 (en) 2014-11-28
NO330421B1 (no) 2011-04-11
NO317555B1 (no) 2004-11-15
EP0799037B1 (de) 2006-09-20
CA2208836A1 (en) 1996-07-11
EP1712232A1 (de) 2006-10-18
ES2144980T3 (es) 2007-03-16
NO973023L (no) 1997-08-19
EP0799037A1 (de) 1997-10-08
AU707541B2 (en) 1999-07-15
CN1935141B (zh) 2013-04-24
WO1996020708A1 (en) 1996-07-11
AU4512696A (en) 1996-07-24
SK88897A3 (en) 1998-02-04
MX9704793A (es) 1997-10-31
NZ300398A (en) 2001-04-27
NO973023D0 (no) 1997-06-27
EP0799037A4 (de) 1998-05-06
CA2208836C (en) 2001-12-04
EP1078633A3 (de) 2001-03-07
CN1935141A (zh) 2007-03-28
DK0799037T3 (da) 2007-02-12
KR100442675B1 (ko) 2004-10-14
CN1267098C (zh) 2006-08-02
DE799037T1 (de) 2000-10-05
HK1008185A1 (en) 1999-05-07

Similar Documents

Publication Publication Date Title
ATE339956T1 (de) Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin
KR900015730A (ko) 정신장해 치료방해
HUP9904362A2 (hu) Eljárás felső légúti allergiás tünetek kezelésére hisztamin H1 és H3 receptor-antagonisták kombinációjával
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
KR950703951A (ko) 광학적으로 순수한 r-케토로락을 포함하는 조성물과 무통과 해열치료에 이를 사용하는 방법(antipyretic and analgesic methods and compositions containing optically pure r-ketorolac)
ATE187642T1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
NO893256L (no) Fremgangsmaate for fremstilling av furyltiazolderivater.
DE69307702T2 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
SE9903985D0 (sv) Use of nitric oxide
SE0200598D0 (sv) Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences
EP0453337A3 (en) Use of hexetidine or its derivatives or salts for the preparation of a pharmaceutical composition for ophthalmic use
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
NO881798D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0799037

Country of ref document: EP